In April 2021
Arch Biopartners entered into worldwide License Agreement to re-purpose Cilastatin. Cilastatin was published
Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury and additionally
Nephroprotective effects of cilastatin in people at risk of acute kidney injury: A systematic review and meta-analysis "Patients at risk of AKI treated with imipenem-cilastatin developed AKI less frequently and had better short term kidney function than those receiving control or comparator antibiotics"
In Feb 2024
Arch Biopartners had Pre-IND meeting with FDA to discuss repurposing Cilastatin as a new treatment to prevent Acute Kidney Injury.
Arch has agreed to be an industry partner with a group of Canadian clinical researchers in a planned Phase II clinical trial targeting drug toxin-related AKI. In June 2024
Arch Bioparnters announced Manufacturing of Cilastatin Drug Product , the first ever stand alone cilastatin drug product.
This all falls under a strong
Patent Arch Biopartners was issued protecting the method of use for the dipeptidase-1(DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.
Arch is currently dosing patients with its lead candidate in AKI, LSALT Peptide in Canada and Turkey.